ArticleJournal of clinical medicine2021
Fecal Microbial Transplantation versus Mesalamine Enema for Treatment of Active Left-Sided Ulcerative Colitis-Results of a Randomized Controlled Trial.
Article in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 8 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Gut microbiota dysbiosis in the pathogenesis of ulcerative colitis and the therapeutic efficacy of fecal microbiota transplantation: a meta-analysis.BMC gastroenterology · 2026Pooled it
- Comparative Effectiveness and Safety of Fecal Microbiota Transplantation in Ulcerative Colitis: An Updated Systematic Review and Meta-Analysis.Advances in therapy · 2026Pooled it
- Management of paediatric ulcerative colitis, part 1: Ambulatory care-An updated evidence-based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organisation.Journal of pediatric gastroenterology and nutrition · 2025Guideline
- Fecal microbiota transplantation for patients with ulcerative colitis: a systematic review and meta-analysis of randomized control trials.Techniques in coloproctology · 2025Pooled it
- Targeting gut microbiota dysbiosis in inflammatory bowel disease: a systematic review of current evidence.Frontiers in medicine · 2025Pooled it
- Effectiveness and safety of non-pharmacological therapies for the treatment of inflammatory bowel disease: a network meta-analysis.Frontiers in medicine · 2025Pooled it
- Safety comparison of single-donor and pooled fecal microbiota transfer product preparation in ulcerative colitis: systematic review and meta-analysis.BMC gastroenterology · 2024Pooled it
- Fecal microbiota transplantation as a therapy for treating ulcerative colitis: an overview of systematic reviews.BMC microbiology · 2023Pooled it
- Mechanistic insights into fecal microbiota transplantation for the treatment of ulcerative colitis: analysis of the STOP-Colitis trial.Journal of Crohn's & colitis · 2026Trial
- Fecal Microbiota Transplantation BeyondJournal of Korean medical science · 2026Review
- The Gut Microbiome Dependency Continuum in Drug Discovery: A Unified Pharmacology Framework Linking Clinical Drugs, Natural Products, and Engineered Microbial Therapeutics.Biotech (Basel (Switzerland)) · 2026Review
- Review
- Multiscale Interface Engineering for Orthopedic and Dental Implants: A Review.Journal of functional biomaterials · 2026Review
- Fecal Microbiota Transplantation in 2025: Two Steps Forward, One Step Back.Current gastroenterology reports · 2026Review
- One therapy, many targets: redefining ulcerative colitis treatment through fecal microbiota transplantation.Therapeutic advances in gastroenterology · 2026Review
- Microbiota transplant therapy in inflammatory bowel disease: advances and mechanistic insights.Gut microbes · 2025Review
- Impact of Gut Microbiome on Gut Permeability in Liver and Gut Diseases.Microorganisms · 2025Review
- Role of gut microbiota and mesenteric adipose tissue in the pathology of Crohn's disease: Potential therapeutic targets.World journal of gastroenterology · 2025Article
- Current Approaches to Ulcerative Colitis Management: A Comprehensive Overview of Methodologies and Treatments.Infectious disorders drug targets · 2025Review
- Gut microbiota dysbiosis in inflammatory bowel disease: interaction with intestinal barriers and microbiota-targeted treatment options.Frontiers in cellular and infection microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 1 country.
Funding
Abstract
BACKGROUND AND
aimsUlcerative colitis (UC) is a chronic inflammatory disease. Fecal microbial transplantation (FMT) is a promising alternative treatment.
methodsThis multicenter, open-label, noninferiority trial randomized patients with active left-sided UC (Mayo score 4-10) equally to FMT or 5-aminosalicylic acid (5-ASA) enemas. FMT enemas were administered five times in the first week and then once weekly for 5 weeks. 5-ASA enemas were administered daily for 2 weeks and then every other day. The primary study endpoint was clinical remission, with a total Mayo score ≤2 at week 12 with no subscore >1.
resultsSixty-one patients were screened; 45 were enrolled and randomized to FMT (
conclusionFMT is an effective treatment for left-sided UC and increased recipient microbiome diversity. Targeted microbiome modification may improve FMT efficacy. Further investigation is needed to guide donor and patient selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.